Humacyte, Inc.
HUMA
$3.13
$0.123.99%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | 29.42% | -15.02% | -34.16% | -39.46% | -48.76% |
| Gross Profit | -29.42% | 14.97% | 32.77% | 37.92% | 47.34% |
| SG&A Expenses | 20.51% | 13.73% | -8.76% | -10.89% | -10.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.88% | 18.16% | 16.56% | 12.53% | 5.04% |
| Operating Income | -22.88% | -18.21% | -18.38% | -14.62% | -7.18% |
| Income Before Tax | -71.01% | -57.49% | -263.22% | -825.83% | -360.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.01% | -57.49% | -263.22% | -825.83% | -360.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.01% | -57.49% | -263.22% | -825.83% | -360.31% |
| EBIT | -22.88% | -18.21% | -18.38% | -14.62% | -7.18% |
| EBITDA | -26.01% | -21.20% | -21.39% | -16.83% | -8.12% |
| EPS Basic | -54.99% | -47.09% | -257.95% | -822.74% | -359.48% |
| Normalized Basic EPS | -15.09% | -13.70% | -15.87% | -11.69% | -2.51% |
| EPS Diluted | -54.99% | -47.09% | -248.19% | -763.95% | -371.45% |
| Normalized Diluted EPS | -15.09% | -13.70% | -16.09% | -11.90% | -3.14% |
| Average Basic Shares Outstanding | 9.00% | 5.25% | 1.50% | 0.36% | 0.29% |
| Average Diluted Shares Outstanding | 9.00% | 5.25% | 1.28% | 0.14% | -0.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
